There is one clinical trial.
To investigate safety and tolerability of BI 764198 in healthy male subjects following oral
administration of multiple rising doses per day over 14 days and to investigate the food
effect on the relative bioavailability of BI 764198.
Primary Outcomes
Measure: percentage of subjects with drug-related adverse events Time: Up to Day 34
Secondary Outcomes
Measure: MRD Part - AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ) Time: Up to Day 34
Measure: MRD Part -Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) Time: Up to Day 34
Measure: MRD Part -tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state) Time: Up to Day 34
Measure: FE Part - AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) Time: Up to Day 17
Measure: FE Part - Cmax (maximum measured concentration of the analyte in plasma) Time: Up to Day 17
Measure: FE Part - tmax (Time from (last) dosing to the maximum measured concentration of the analyte in plasma) Time: Up to Day 17